Pharsight

1. Goprelto patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040032	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)
US9867815	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)
US10016407	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)
US10413505	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)
US10933060	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)
US10987347	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)
US10973811	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)
US10420760	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)
US10894012	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)
US10149843	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)
US10231961	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)
US10857095	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (12 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 14, 2022

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 14 December, 2021

Market Authorisation Date: 14 December, 2017

Treatment: Method of administering a local anesthetic to the mucous membranes in geriatric patients; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject...

Dosage: SOLUTION;NASAL

Strength	Dosage	Availability
4%	SOLUTION;NASAL	Prescription

GOPRELTO family patents

2. Levolet patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231931	GENUS LIFESCIENCES	Thyroid hormone oral dosage forms and methods of using the same	Mar, 2038 (13 years from now)
US10406108	GENUS LIFESCIENCES	Thyroid hormone oral dosage forms and methods of using the same	Mar, 2038 (13 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 06 June, 2003

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription

LEVOLET family patents

3. Yosprala patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP02734602A	2011-04-21	CHATFIELD PHARMACEUTICALS LIMITED	Patent maintained as amended
EP02734602A	2011-04-15	STRAWMAN LIMITED	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US6926907	May, 2015	Terminated-Denied	POZEN Inc.	Coalition for Affordable Drugs VII LLC

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9364439	GENUS LIFESCIENCES	Pharmaceutical compositions for the coordinated delivery of NSAIDs	May, 2022 (1 year, 10 months ago)
US6926907	GENUS LIFESCIENCES	Pharmaceutical compositions for the coordinated delivery of NSAIDs	Feb, 2023 (1 year, 1 month ago)
US8206741	GENUS LIFESCIENCES	Pharmaceutical compositions for the coordinated delivery of NSAIDs	Feb, 2023 (1 year, 1 month ago)
US9987231	GENUS LIFESCIENCES	Compositions and methods for delivery of omeprazole plus acetylsalicylic acid	Jan, 2033 (8 years from now)
US9539214	GENUS LIFESCIENCES	Compositions and methods for delivery of omeprazole plus acetylsalicylic acid	Mar, 2033 (8 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Sep 14, 2019

Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient

Market Authorisation Date: 14 September, 2016

Treatment: Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers; For secondary prevention of cardi...

Dosage: TABLET, DELAYED RELEASE;ORAL

Pharsight

Genus Lifesciences patents expiration

1. Goprelto patents expiration

GOPRELTO family patents

2. Levolet patents expiration

LEVOLET family patents

3. Yosprala patents expiration

YOSPRALA family patents

Related content

Strength	Dosage	Availability
325MG;40MG	TABLET, DELAYED RELEASE;ORAL	Discontinued
81MG;40MG	TABLET, DELAYED RELEASE;ORAL	Discontinued